Edwards Lifesciences Corp
For the period ended Mar 31, 2025. Filed May 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 6, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Rule 10b5-1 Trading Plans
During the first quarter of 2025, the following is a list of activity by any executive officer or director with respect to a 10b5-1 trading plan intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act (each, a "Plan"):
On February 27, 2025, Donald E. Bobo, Jr., Corporate Vice President, Strategy & Corporate Development, entered into a Plan providing for the potential sale of 66,650 shares of the Company’s stock commencing June 2, 2025. Mr. Bobo's Plan terminates on the earlier of April 16, 2026, or the date all shares are sold.
On February 27, 2025, Larry L. Wood, Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart, entered into a Plan providing for the potential sale of 53,700 shares of the Company’s stock commencing May 30, 2025. Mr. Wood's Plan terminates on the earlier of April 16, 2026, or the date all shares are sold.
On February 28, 2025, Bernard J. Zovighian, Chief Executive Officer and Director, entered into a Plan providing for the sale of an estimated 62,833* shares of the Company’s stock commencing May 30, 2025. Mr. Zovighian's Plan terminates on the earlier of February 9, 2026, or the date all shares are sold.
- This is an estimate of the number of shares to be sold under the Plan, which are subject to the conditions of the plan.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.